Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2
Animals
Apolipoprotein B-100
/ genetics
Atherosclerosis
/ diagnostic imaging
Disease Models, Animal
Fluorodeoxyglucose F18
Glutamine
/ analogs & derivatives
Male
Mice
Mice, Inbred C57BL
Plaque, Atherosclerotic
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
Receptors, LDL
/ deficiency
18F-fluoroglutamine
PET/CT
atherosclerosis
inflammation
macrophages
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
11
2021
accepted:
03
01
2022
entrez:
11
2
2022
pubmed:
12
2
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Increased glutamine metabolism by macrophages is associated with development of atherosclerotic lesions. Positron emission tomography/computed tomography (PET/CT) with a glutamine analog (2S,4
Identifiants
pubmed: 35145523
doi: 10.3389/fimmu.2022.821423
pmc: PMC8822173
doi:
Substances chimiques
Apolipoprotein B-100
0
Receptors, LDL
0
Glutamine
0RH81L854J
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
821423Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243895
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Palani, Miner, Virta, Liljenbäck, Eskola, Örd, Ravindran, Kaikkonen, Knuuti, Li, Saraste and Roivainen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res. 2017 Mar 15;77(6):1476-1484
pubmed: 28202527
J Nucl Med. 2011 Jul;52(7):1005-8
pubmed: 21680688
Immunity. 2015 Mar 17;42(3):419-30
pubmed: 25786174
J Nucl Med. 2014 Oct;55(10):1699-705
pubmed: 25214643
Mol Imaging Biol. 2016 Feb;18(1):18-23
pubmed: 25971659
JACC Cardiovasc Imaging. 2011 Dec;4(12):1294-301
pubmed: 22172786
J Nucl Cardiol. 2014 Dec;21(6):1112-28; quiz 1129
pubmed: 25124827
Sci Transl Med. 2015 Feb 11;7(274):274ra17
pubmed: 25673762
Front Immunol. 2018 Mar 19;9:508
pubmed: 29616026
Sci Rep. 2020 Aug 12;10(1):13593
pubmed: 32788595
Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):780-92
pubmed: 26678270
Mol Pharm. 2018 Aug 6;15(8):3448-3455
pubmed: 29985631
J Nucl Med. 2012 Jan;53(1):55-8
pubmed: 22128324
Mol Imaging Biol. 2020 Aug;22(4):969-978
pubmed: 31993927
Nature. 2013 Apr 11;496(7444):238-42
pubmed: 23535595
Biochim Biophys Acta. 2016 Oct;1863(10):2531-9
pubmed: 26724577
J Nucl Med. 2011 Dec;52(12):1947-55
pubmed: 22095958
Front Oncol. 2021 Oct 12;11:760732
pubmed: 34712616
J Am Coll Cardiol. 2011 Aug 2;58(6):603-14
pubmed: 21798423
J Nucl Med. 2021 Aug 1;62(8):1154-1162
pubmed: 33277391
Eur Heart J. 2018 Jun 21;39(24):2301-2310
pubmed: 29562241
Am J Physiol Endocrinol Metab. 2021 May 1;320(5):E989-E998
pubmed: 33843281
J Nucl Med Technol. 2013 Mar;41(1):32-4
pubmed: 23318199
J Nucl Cardiol. 2015 Apr;22(2):319-24
pubmed: 24925623
Sci Rep. 2018 Jun 26;8(1):9720
pubmed: 29946129
Radiology. 2018 May;287(2):667-675
pubmed: 29388903
Nat Rev Cardiol. 2015 Jan;12(1):10-7
pubmed: 25367649
Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1840-1848
pubmed: 28798141
J Nucl Med. 2013 Sep;54(9):1661-7
pubmed: 23886729
Front Oncol. 2021 Oct 07;11:730358
pubmed: 34692505